WO2016122172A1 - Composition pour favoriser la santé capillaire ou la pousse des cheveux, présentant une stabilité améliorée et contenant de la mélatonine - Google Patents
Composition pour favoriser la santé capillaire ou la pousse des cheveux, présentant une stabilité améliorée et contenant de la mélatonine Download PDFInfo
- Publication number
- WO2016122172A1 WO2016122172A1 PCT/KR2016/000742 KR2016000742W WO2016122172A1 WO 2016122172 A1 WO2016122172 A1 WO 2016122172A1 KR 2016000742 W KR2016000742 W KR 2016000742W WO 2016122172 A1 WO2016122172 A1 WO 2016122172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hair growth
- melatonin
- hair
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 229960003987 melatonin Drugs 0.000 title claims abstract description 91
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 230000003779 hair growth Effects 0.000 title claims abstract description 82
- 230000003646 hair health Effects 0.000 title abstract 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 76
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 66
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 39
- 239000011703 D-panthenol Substances 0.000 claims abstract description 39
- 235000004866 D-panthenol Nutrition 0.000 claims abstract description 39
- 229960002685 biotin Drugs 0.000 claims abstract description 39
- 235000020958 biotin Nutrition 0.000 claims abstract description 39
- 239000011616 biotin Substances 0.000 claims abstract description 39
- 229960003949 dexpanthenol Drugs 0.000 claims abstract description 39
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 38
- 239000011570 nicotinamide Substances 0.000 claims abstract description 37
- 201000004384 Alopecia Diseases 0.000 claims abstract description 34
- 208000024963 hair loss Diseases 0.000 claims abstract description 24
- 230000003676 hair loss Effects 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 13
- XFLVBMBRLSCJAI-UHFFFAOYSA-N biotin amide Natural products N1C(=O)NC2C(CCCCC(=O)N)SCC21 XFLVBMBRLSCJAI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000001737 promoting effect Effects 0.000 claims description 34
- 210000002268 wool Anatomy 0.000 claims description 32
- 238000009472 formulation Methods 0.000 claims description 31
- 239000004611 light stabiliser Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000012965 benzophenone Substances 0.000 claims description 17
- 239000003381 stabilizer Substances 0.000 claims description 17
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 16
- -1 parahydroxybenzoic acid ester Chemical class 0.000 claims description 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 8
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 3
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 3
- 230000003658 preventing hair loss Effects 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- 229910018134 Al-Mg Inorganic materials 0.000 claims description 2
- 229910018467 Al—Mg Inorganic materials 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 150000003852 triazoles Chemical group 0.000 claims description 2
- DJENHUUHOGXXCB-UHFFFAOYSA-N 2-butyl-6-methoxyphenol Chemical compound CCCCC1=CC=CC(OC)=C1O DJENHUUHOGXXCB-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 14
- 210000004761 scalp Anatomy 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 36
- 210000004209 hair Anatomy 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 19
- 210000003780 hair follicle Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 230000012010 growth Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000003128 head Anatomy 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 231100000360 alopecia Toxicity 0.000 description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 7
- 230000003698 anagen phase Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229960003632 minoxidil Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000012430 stability testing Methods 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000035617 depilation Effects 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000000176 photostabilization Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 230000003752 improving hair Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- YSNSYLNGBYMCGL-UHFFFAOYSA-N 2-hydroxybenzoic acid octane Chemical compound CCCCCCCC.OC(=O)c1ccccc1O YSNSYLNGBYMCGL-UHFFFAOYSA-N 0.000 description 1
- LLIANSAISVOLHR-GBCQHVBFSA-N 5-[(3as,4s,6ar)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LLIANSAISVOLHR-GBCQHVBFSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000181331 Saron Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 229940024874 benzophenone Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000049 endocrine disruptor Toxicity 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003793 hair pigmentation Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002432 hydroperoxides Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003762 total hair loss Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition for promoting hair growth, wool or hair growth which has dramatically improved stability, dosage compliance and therapeutic effect.
- Human hair loss cycle is largely divided into anagen, catagen and telogen.
- the growth phase is a time when hair growth grows rapidly due to vigorous cell division and cell division.
- the lifespan of the growing season varies depending on the type of hair, but for hair it is about 3-6 years.
- Growth hair accounts for 80-90% of the total hair, and hair loss is progressing in people who have short hair growth periods and long hair periods, resulting in a decrease in the proportion of growth hairs in the overall hair.
- the degenerative phase is the end of the growth phase of the hair and the production of the hair gradually slows down, resulting in cell division and growth stopping.
- the degenerative lifespan is about 1-1.5 months and about 1% of the hair belongs to this stage.
- Resting phase is the final stage of growth when hair follicles and papillae are completely separated, causing hair follicles to atrophy and hair roots to rise upwards and hair fall out.
- the rest period lasts 3-4 months and 4-14% of all hairs fall into this stage.
- the activity of the nipple is active again, new nipples are created, and the hair in the resting period is pushed out of the scalp.
- alopecia The main cause of alopecia is known to be related to male hormones and steroid hormones, and there are reports that stress is largely involved. Recently, it has been suggested that renal dysfunction is a direct cause of hair loss, Many are unknown about the cause or mechanism of occurrence.
- Finasteride is a drug that inhibits the 5 ⁇ -reductase enzyme, which converts testosterone to dihydrotestosterone (DHT), and serves to grow soft hair into thick and long hair. It is effective in improving hair loss in the short term, but side effects such as erectile dysfunction, decreased sexual function, and breast enlargement in men have been reported.
- Minoxidil is a drug that can be purchased without a doctor's prescription because of its safety and effectiveness. In December 1997, it was approved by the US FDA as the first anti-hair loss treatment. This drug has the effect of promoting hair growth by improving blood circulation and opening potassium channels, but it may cause local reactions such as itching and rashes, and tachycardia.
- Melatonin is a hormone produced and secreted by the pineal gland of the brain and is made through tryptophan (serotonin).
- Melatonin is an endocrine modulator that has the function of regulating hair growth, pigmentation or peeling, is capable of controlling the hair cycle, and promotes hair growth as a DNA repair derivative.
- melatonin may be an alternative to minimize various side effects of existing hair loss treatments, but it is difficult to commercialize it in the form of external preparations due to its low light stability and relatively low solubility. Therefore, there is a need for the development of a pharmaceutical composition containing melatonin as a pharmacological component and having improved storage stability and excellent taking convenience while optimizing drug delivery efficiency and drug persistence.
- the present inventors have made diligent research efforts to develop a composition for promoting hair growth, wool, or hair growth which has less side effects than conventional hair loss treatment agents and has excellent storage stability and administration convenience.
- the inclusion of melatonin, dexpanthenol, biotin and nicotinic acid amide in certain amounts improves the light stability of pharmacological melatonin, improves the transparency of the formulation, and maximizes drug absorption, especially transdermal penetration.
- the present invention has been completed by discovering that the stability of the formulation can be greatly improved by minimizing chemical and physical changes caused by ultraviolet rays during storage.
- Another object of the present invention to provide a method for promoting hair growth, wool or hair growth.
- the present invention provides a composition for promoting hair growth, wool or hair growth comprising melatonin, dexpanthenol, biotin and nicotinic acid amide as an active ingredient.
- the present inventors have made diligent research efforts to develop a composition for promoting hair growth, wool, or hair growth which has less side effects than conventional hair loss treatment agents and has excellent storage stability and administration convenience.
- the inclusion of melatonin, dexpanthenol, biotin and nicotinamide in a certain amount improves the light stability of the pharmacological melatonin, improves the transparency of the formulation, and improves the absorption of the drug, It has been found that the physical change can be minimized to significantly improve the stability of the formulation.
- the antioxidant effect can be maximized to prevent inflammation and show anti-inflammatory effects.
- promoting hair growth means promoting the production and growth of hair and ultimately increasing the proportion of growing hair in total hair. Therefore, the term means inhibiting hair loss caused by decreasing the specific gravity of growing hair, and therefore has the same meaning as “improve hair loss”, “hair loss prevention” and “hair loss treatment”.
- melatonin used in the present invention is included in an amount of 0.001-1.0 wt% based on the total amount of the composition of the present invention. More specifically, it is included in 0.005-0.5% by weight, even more specifically, it is included in 0.01-0.3% by weight, and most specifically, it is included in 0.05-0.2% by weight.
- dexpanthenol used in the present invention is included in an amount of 0.01-0.5% by weight based on the total amount of the composition of the present invention. More specifically, it is included at 0.02-0.4% by weight, even more specifically, it is included at 0.05-0.3% by weight, and most specifically, it is included at 0.1-0.2% by weight.
- the biotin (biotin) used in the present invention is included in 0.001-0.05% by weight relative to the total amount of the composition of the present invention. More specifically, it is included in 0.002-0.04% by weight, even more specifically, it is included in 0.005-0.03% by weight, most specifically, it is included in 0.01-0.02% by weight.
- nicotinamide used in the present invention is included at 0.006-0.3% by weight based on the total amount of the composition of the present invention. More specifically, it is included as 0.012-0.24% by weight, even more specifically, it is included as 0.03-0.18% by weight, and most specifically, it is included as 0.06-0.12% by weight.
- the composition of the present invention further comprises a light stabilizer.
- Photostabilization of the present invention includes, but is not limited to, the trapping of radicals, the decomposition of hydroperoxides, the trapping of heavy metals, and the stabilization by quenching of singlet oxygen, and possible physical and chemical changes due to exposure to visible and ultraviolet light. It includes any mechanism that blocks or mitigates.
- the light stabilizers used in the present invention are, for example, triazole-based, benzophenone-based, hindered amine light stabilizer (HALS), hindered phenolic light stabilizer (Hindered Phenol Light Stabilizer), Al-Mg (aluminum Magnesium-based stabilizers, but is not limited thereto.
- HALS hindered amine light stabilizer
- Hindered Phenol Light Stabilizer hindered phenolic light stabilizer
- Al-Mg aluminum Magnesium-based stabilizers, but is not limited thereto.
- the light stabilizer used in the present invention is benzophenone. More specifically, the benzophenone is included in an amount of 0.008-0.5% by weight, more specifically 0.04-0.3% by weight, most specifically 0.08-0.2% by weight based on the total amount of the composition of the present invention. do.
- the composition of the present invention further comprises a formulation stabilizer.
- Formulation stabilizers are, for example, parahydroxybenzoic acid ester derivatives, pyrrolidinone derivatives, alcohols, phenol derivatives, thimerosal, acetic anhydride, sodium carboxylate, lauryl sulfate (lauryl sulfate), sulfide compounds, sulfites, ascorbic acid, retinol, recotinol, tocopherol, butyl hydroxy anisole, but are not limited thereto.
- the agent stabilizer used in the present invention is methyl-2-pyrrolidinone. More specifically, the methyl-2-pyrrolidinone is included in the amount of 0.05-2.0% by weight, even more specifically 0.1-1.5% by weight, most specifically 0.5- 1.0 wt%.
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier in addition to the above-described active ingredient.
- Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils, and the like. It doesn't happen.
- the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
- a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, a kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mann
- Suitable dosages of the pharmaceutical compositions of the present invention vary depending on factors such as the formulation method, mode of administration, age, weight, sex, pathological condition, food, time of administration, route of administration, rate of excretion, and response to response of the patient. Can be. Preferred dosages of the pharmaceutical compositions of the invention are in the range of 0.001-100 mg / kg on an adult basis.
- the pharmaceutical composition of the present invention may be administered orally or parenterally, and when administered parenterally, may be administered topically to the skin, subcutaneous infusion, transdermal administration, or the like.
- the administration is preferably applied topically to the scalp or through transdermal administration.
- compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of solutions, suspensions, syrups, emulsions or toners, lotions, creams and shampoos in oils or aqueous media, or in the form of extracts, powders, granules, tablets or capsules, It may further include.
- the pharmaceutical composition of the present invention is an external skin composition.
- the formulation of the external composition for skin is not particularly limited, but a powder, gel, ointment, cream, liquid or aerosol formulation is preferred.
- the gel base material of the external skin preparation is carbomer, polyethylene glycol, polypropylene glycol, polyacrylic acid, carboxymethyl cellulose, hydroxymethyl cellulose. 1 selected from (Hydroxymethylcellulose), polyvinylpyrrolidone, gelatin, gelatin, alginate salt, chitin or chitosan derivatives, hyaluronic acid and collagen Species or two or more kinds may be used, but are not limited thereto.
- composition of the present invention can be used as an external skin composition in the form of a topical application to the scalp.
- the pharmaceutical composition of the present invention can be used for promoting hair growth, wool, or hair growth of all animals including humans, and the subject is not limited to humans.
- the invention is a cosmetic composition.
- Antioxidant composition of the present invention can be prepared in the form of hair growth, wool, or cosmetic composition for promoting hair growth.
- the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nourishing lotion, lotion, nourishing cream, massage cream, essence, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
- the carrier component is animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide. This can be used.
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
- solvents, solubilizers or emulsions are used as carrier components, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
- liquid carrier diluents such as water, ethanol or propylene glycol
- suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
- the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
- Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
- ingredients included in the cosmetic composition of the present invention include ingredients conventionally used in cosmetic compositions, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. It may include.
- the invention is a functional food composition.
- Functional food compositions of the present invention include ingredients that are commonly added in the manufacture of food, and include, for example, proteins, carbohydrates, fats, nutrients and seasonings.
- ingredients that are commonly added in the manufacture of food, and include, for example, proteins, carbohydrates, fats, nutrients and seasonings.
- flavoring agents or natural carbohydrates may be included as additional ingredients in addition to the active ingredient.
- natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.); Disaccharides (eg maltose, sucrose, etc.); oligosaccharide; Polysaccharides (eg, dextrins, cyclodextrins, etc.); And sugar alcohols (eg, xylitol, sorbitol, erythritol, and the like).
- flavoring agent natural flavoring agents (e.g., taumartin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be used.
- natural flavoring agents e.g., taumartin, stevia extract, etc.
- synthetic flavoring agents e.g., saccharin, aspartame, etc.
- the present invention provides hair growth and wool comprising 0.001-1.0% by weight of melatonin, 0.01-0.5% by weight of dexpanthenol, 0.001-0.05% by weight of biotin and 0.006-0.3% by weight of nicotinic acid amide as active ingredients. Or it provides a pharmaceutical composition for promoting hair growth.
- the present aspect of the hair growth, wool or hair growth promoting composition is another aspect of the hair growth, wool or hair growth promoting composition already described above to clearly limit the content of the active ingredient, the other aspect of the invention All the contents described in the detailed description are used, and overlapping contents will be omitted to avoid excessive complexity of the description.
- the present invention provides a composition for preventing or treating hair loss comprising melatonin, dexpanthenol, biotin and nicotinamide as an active ingredient.
- hair loss prevention means increasing the specific gravity of growth hair, thereby preventing hair loss caused by decreasing the specific gravity of the growth phase hair
- hair loss treatment herein refers to the specific gravity of the growth phase hair described above.
- Increasing means slowing the progression of hair loss, suppressing the symptoms of hair loss, and ultimately reducing the area of the scalp of the hair off state.
- One aspect of the present invention uses the contents described for the composition for promoting hair growth, wool or hair growth, which is another aspect of the present invention described above, and overlapping contents will be omitted to avoid excessive complexity of the present specification.
- Another aspect of the present invention is a pharmaceutical composition for preventing or treating hair loss comprising 0.001-1.0% by weight of melatonin, 0.01-0.5% by weight of dexpanthenol, 0.001-0.05% by weight of biotin and 0.006-0.3% by weight of nicotinic acid amide as active ingredients.
- composition for preventing or treating hair loss is clearly defined in the content of the active ingredient in another aspect of the composition for preventing or treating hair loss described above, described in the detailed description of the invention with respect to the other aspect All contents are used, and overlapping contents will be omitted in order to avoid excessive complexity of the description of the present specification.
- Another aspect of the present invention includes administering to a subject in need thereof a pharmaceutically effective amount of the composition for promoting hair growth, wool or hair growth comprising melatonin, dexpanthenol, biotin and nicotinamide as an active ingredient.
- a pharmaceutically effective amount of the composition for promoting hair growth, wool or hair growth comprising melatonin, dexpanthenol, biotin and nicotinamide as an active ingredient.
- the term "pharmaceutically effective amount” means an amount sufficient to promote hair growth, wool or hair growth of a subject using the above-described composition, and to achieve the effect of preventing, reducing or treating hair loss symptoms.
- the term “subject” refers to any animal including a human, and is not particularly limited, and particularly refers to a hair, wool or an object in need of promoting hair growth. Since the method of the present invention relates to a method for administering the above-described hair growth, wool or hair growth promoting composition to a subject, the overlapping description is used, and the description is omitted to avoid excessive complexity of the description. .
- Another aspect of the present invention comprises 0.001-1.0% by weight of melatonin, 0.01-0.5% by weight of dexpanthenol, 0.001-0.05% by weight of biotin and 0.006-0.3% by weight of nicotinic acid amide as active ingredients. It provides a method for promoting hair growth, wool or hair growth comprising administering a pharmaceutically effective amount of a to a subject in need thereof.
- the method of the present invention relates to a method for administering the above-described hair growth, wool or hair growth promoting composition to a subject, and the specific content of the components of the hair growth, wool or hair growth promoting method described above in detail.
- overlapping content is used, and the description is omitted to avoid excessive complexity of the description.
- the present invention is hair growth, wool or hair growth promoting pharmaceutical composition, cosmetic composition or functional food composition comprising melatonin, dexpanthenol, biotin and nicotinamide as active ingredients, hair growth, wool or hair growth using the above-mentioned composition Provide a method of promotion.
- composition of the present invention stabilizes the preparation and significantly inhibits scalp inflammation while improving the light stability of the pharmacologically active melatonin, thereby maximizing the hair growth or wool effect.
- composition of the present invention can be usefully used as an effective hair regrowth, wool promoter, or prevention or treatment of hair loss at the same time increased light stability, preservation, ease of administration and therapeutic effect.
- FIG. 1 shows the results of AREA OF HAIR RESTORATION 9 days after test substance treatment in dexamethasone induced alopecia C57BL / 6 mouse model.
- the arrowed part of FIG. 1 shows the range analyzed using ImageJ software (NIH, Bethesda, MD) after photographing the application site with a digital camera.
- Example 11 Comparative Example 1 Melatonin 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.01 0.2 - Dexpanthenol - 0.1 - - 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Biotin - - 0.01 - 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Nicotinic acid amide - - - 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 N-methyl-2-pyridyridone - - - - 0.5 One 0.5 0.5 0.5 0.5 0.5 - Benzophenone - - - - - - - 0.04 0.08 0.08 0.08 - Polyoxyl 40
- Examples 1 to 5 are intended to establish a basic formulation formulation for establishing a formulation suitable for the efficacy, effect and properties of the composition of the present invention
- Example 8 and Example 9 is the application of the composition to ensure the stability of the formulation from chemical and physical changes caused by ultraviolet light.
- Free radicals are considered as a causative agent of aging (eg, hair loss, skin aging).
- the antioxidant activity was measured by measuring the free radical scavenging activity according to the use of a light stabilizer.
- a DPPH test group sample 0.1% by weight of melatonin, 0.01% by weight of biotin, 0.06% by weight of nicotinic acid amide and 0.1% by weight of dexpanthenol were stirred for 10 minutes until completely dissolved in ethanol. Then, a DPPH (1-diphenyl-2-picrylhydrazyl) solution was prepared with 80 ⁇ g / ml ethanol, and each fraction was dissolved in ethanol in 1 ml of the solution to a concentration of 2 mg / ml.
- the color change of DPPH was then measured by absorbance at 517 nm at the wavelength of absorption using a UV spectrophotometer, and the inhibitory effect was calculated by calculating the magnitude of activity into the following equation:
- Experimental results Melatonin, biotin, nicotinamide And dexpanthenol, the antioxidant effect was measured best, and when dexpanthenol, biotin, nicotinamide were used alone, the antioxidant effect was significantly higher than that containing all of melatonin, biotin, nicotinic acid amide, and dexpanthenol. The result is a decrease.
- Table 3 The results are shown in Table 3.
- a composition comprising melatonin, biotin, dexpanthenol and nicotinic acid amide as an active ingredient is prepared, and the effect of the composition of the active ingredient on the stability of melatonin Measured through stability test.
- the photostability chamber was tested under VIS 40 klux conditions in accordance with Stability Testing: Photo stability Testing of New Drug Substances and Products (Q1b) of the International Conference on Harmonization (ICH) guidelines.
- test group (Example 1-Example 5) was prepared according to the method of Table 2. And 50g each of the test group was filled in a pump-type transparent container (HDPE). The filled sample was placed in the irradiation direction in the light stability chamber and sampled by 2 mL at each time interval. When the sampling was completed, it was quantitatively analyzed by liquid chromatography (HPLC).
- HPLC liquid chromatography
- HPLC analysis conditions were the detector, ultraviolet ultraviolet photometer (wavelength 225 nm) column C18 (4.6 mm x 50 mm, 1.8 ⁇ m) or equivalent column, mobile phase 0.018 mol / L phosphate buffer (pH 3.0): acetonitrile ( 90: 10)
- the flow rate was 1 mL / min
- the injection amount was 50 ⁇ L
- the temperature was 25 ° C.
- the injection order was standard solution (3 times) and sample solution (2 times).
- the stability of the formulation composition was higher in the melatonin, biotin, nicotinic acid amide and dexpanthenol group than in the melatonin alone group, and it was noted that mixing the biotin, nicotinic acid amide and dexpanthenol with the melatonin improved the content stability.
- One effect was found. The results are shown in Table 4.
- the phosphate buffer was prepared by dissolving 2.45 g of potassium dihydrogen phosphate in water to 1 L, and then adjusting the pH to 3.0 by adding 20% phosphoric acid.
- each stabilizer (benzophenone, zinc oxide, ethylhexylsalicylate, titanium oxide) was added to 0.1% by weight of melatonin until it was completely dissolved in ethanol for 10 minutes. It was.
- test group was filled in a pump-type transparent container (HDPE).
- HDPE pump-type transparent container
- HPLC analysis conditions were the detector was an ultraviolet absorbance spectrometer (wavelength 225 nm) column was C 18 (4.6 mm x 50 mm, 1.8 ⁇ m) or equivalent column, mobile phase 0.018 mol / L phosphate buffer (pH 3.0): acetonitrile ( 90: 10) The flow rate was 1 mL / min, the injection volume was 50 ⁇ L, the temperature was 25 ° C, and the injection order was standard solution (3 times) and sample solution (2 times).
- the stabilizing activity was measured in the order of methyl-2-pyrrolidinone, ascorbic acid, tocopherol, butyl hydroxyanisole, and the most preferable bar stabilizer as the stabilizing activity of methyl-2-pyrrolidinone. It can be seen that methyl-2-pyrrolidinone can be used.
- the photostabilization activity was measured in the order of benzophenone, zinc oxide, ethyl hexane salicylate, and titanium oxide.
- the photostabilization activity of benzophenone was the best, and as a photostabilizer, benzophenone was most preferably used. there was.
- the results are shown in Table 5 and Table 6.
- the phosphate buffer solution was prepared by dissolving 2.45 g of potassium dihydrogen phosphate in water to 1 L, and then adjusting the pH to 3.0 by adding 20% phosphoric acid.
- Example 1 Example 2
- Example 3 Example 4
- Example 5 Melatonin Melatonin + Dexpanthenol Melatonin + Biotin Melatonin + Nicotinamide Melatonin + Biotin + Nicotinamide + Dexpanthenol 0 100.1 100.1 99.7 99.7 100.0 15 99.8 99.7 99.8 99.6 99.9 30 98.4 99.4 99.5 99.0 99.8 45 98.7 99.2 99.7 99.4 100.0 60 97.9 98.6 99.2 98.6 100.0 75 96.7 98.2 98.0 97.7 99.8 90 95.6 97.7 97.2 96.5 100.3 105 93.9 97.2 96.8 96.0 99.6 120 Not detected 93.7 92.4 90.7 99.3 (Unit: Melatonin Content (%))
- benzophenone can be used as an excellent light stabilizer, but there are some known side effects such as disturbing the endocrine system, which may worsen allergic diseases.
- Biotin, nicotinamide, and dexpanthenol combinations and methyl-2-pyrrolidinone to additionally include the group in melatonin, or to use methyl-2-pyrrolidinone, or to compensate for it while reducing the content of benzophenone It is possible to increase the light stability of melatonin in such a manner as to use.
- the light stability of melatonin is significantly increased and further enhanced by additional inclusion of additional stabilizers or light stabilizers such as methyl-2-pyrrolidinone, benzophenone Stability can be secured.
- the breeding box has a color-coded individual identification card, and the animal room use record sheet is attached at the entrance of the breeding room.
- This test is set to a temperature of 23 ⁇ 3 °C, relative humidity of 55 ⁇ 15%, ventilation times of 10-20 times / hr, lighting time of 12 hours (lighting up from 8 am to 8 pm off) and illuminance of 150 to 300 Lux.
- the study was conducted in Room 2 of the Rodent Breeding Area of the Korean Institute of Animal Science.
- the environmental conditions such as temperature, humidity, ventilation frequency and illumination of the animal room were measured once a week. As a result of environmental measurement, no abnormality was observed that would adversely affect the test results.
- Feed was supplied to Dream Feed of experimental animal feed produced by Cargill Agripurina Co., Ltd. and fed to the feeder freely.
- the rug was used by receiving wooden rugs from Saron Bio.
- mice with no skin scars and pink back skin were selected and randomly grouped. Each group was divided into excipient control group, positive control group (3% minoxidil administration group), HTB005 (1) ⁇ HTB005 (5) administration group to administer the test substance.
- Clinical application was administered through the skin coating, and the test substance was administered once / day and 9 days from the 7th day after hair removal, and dexamethasone was administered once / day and 7 days from the 9th day after hair removal.
- dexamethasone it was applied at 1 mL / head.
- the spray was applied using a spray container (approximately 0.18 mL / 1 time) to spread the skin evenly over a section.
- test substance and the positive control substance were applied using a spray container to spread a 1.5 cm ⁇ 1.5 cm size mold on the depilated skin and spread evenly in a predetermined section.
- Body weight measurement It was measured on the day of hair removal, and once / week thereafter.
- test substance application site was extracted and fixed in 10% neutral buffered formalin solution.
- the tissues were prepared for histopathological examination, followed by H & E (Hematoxylin & Eosin) staining, hair follicle formation, and hair follicle growth rate. According to the hair growth effect evaluation was performed. The number of hair follicles and the growth period was evaluated by photographing using an optical microscope (Olympus BX53, Japan), and then randomly selecting 5 photos for each subject.
- H & E Hematoxylin & Eosin
- Minoxidil has been reported to be effective against androgenetic alopecia (Messenger AG et al, 2004) and was used as a positive control in this study.
- the hair growth area of all the test substance-administered groups showed a tendency higher than that of the excipient control group at 7 days after the start of the test substance administration.
- the hair growth area of the melatonin 0.01% and the melatonin 0.2% administration group tended to be higher than that of the excipient control group, and the hair growth area of the melatonin 0.01% and melatonin 0.2% administration groups was positive in the 12 and 16 days after the start of the administration of the test substance. The higher the tendency, the more likely that the test substance may help to promote hair growth.
- the hair follicle ratio of the melatonin 0.01% and the melatonin 0.2% group tended to be higher than that of the positive control group.
- the hair growth area of the 0.2% melatonin-treated group was higher than that of the excipient control group and the positive control group on all measurement days, and melatonin was observed.
- the 0.01% administration group a higher tendency was observed in all measurement days except the 9th day compared to the excipient control group and the positive control group.
- the number of hair follicles and growth rate of hair follicles of 0.01% melatonin and 0.2% melatonin administration group was higher than that of the excipient control group and the positive control group.
- Rehair area unit % group 9th day G1 1.257 G2 22.33 G3 20 G5 10.1 G6 0.295 G7 37.2
- Active hair follicles represent the proportion of individual hair follicles and hair converted to histopathologic findings in the hair growth test. Histopathological examination is divided into growth stage, resting stage and degenerative stage, and only the ratio of hair follicle growing stage is calculated. The growth stage, resting stage and degeneration stage were determined and determined by comprehensive consideration of the number of hair follicles, the size of hair follicles and the thickness and shape of hair. The calculation method is as follows:
- Active hair follicle ratio number of animals in which the hair removal site is converted to growth / the total number of animals in each test group X 100.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
Abstract
La présente invention concerne une composition pharmaceutique pour favoriser la santé capillaire ou la pousse des cheveux, contenant de la mélatonine, du dexpanthénol, de la biotine et de nicotinamide en tant que principes actifs. La composition selon la présente invention maximise la croissance des cheveux ou les effets liés à la santé des cheveux, par la stabilisation d'une préparation, tout en améliorant la stabilité à la lumière de la mélatonine, qui est un principe pharmacologiquement actif, et en inhibant de façon significative l'inflammation du cuir chevelu. Par conséquent, la composition selon la présente invention peut être utile en tant que promoteur d'une pousse efficace des cheveux ou de la santé des cheveux ou en tant qu'agent pour la prévention ou le traitement de la chute des cheveux, ladite composition augmentant simultanément la stabilité à la lumière, la capacité de conservation, la commodité d'administration et les effets thérapeutiques.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680007880.2A CN107205908B (zh) | 2015-01-30 | 2016-01-22 | 稳定性得到改善的含褪黑激素的育发、养发或生发促进用组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150015524 | 2015-01-30 | ||
KR10-2015-0015524 | 2015-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016122172A1 true WO2016122172A1 (fr) | 2016-08-04 |
Family
ID=56103919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/000742 WO2016122172A1 (fr) | 2015-01-30 | 2016-01-22 | Composition pour favoriser la santé capillaire ou la pousse des cheveux, présentant une stabilité améliorée et contenant de la mélatonine |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101622387B1 (fr) |
CN (1) | CN107205908B (fr) |
WO (1) | WO2016122172A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230128237A (ko) | 2022-02-24 | 2023-09-04 | 주식회사 헬릭스미스 | 양모 촉진용 생약조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61212512A (ja) * | 1985-03-19 | 1986-09-20 | Shiseido Co Ltd | 養毛料 |
JP2969179B2 (ja) * | 1994-12-08 | 1999-11-02 | クレット−ロッホ、ローレ、マリア | 毛髪の成長,及び選択的には皮膚並びに爪の成長を促進し,抜け毛を防止又は抑制するための合成製剤 |
KR20050083836A (ko) * | 2002-10-30 | 2005-08-26 | 아에스아테 아게 어플라이드 사이언스 앤드 테크놀로지 | 멜라토닌, 징코 빌로바, 및 비오틴을 포함하는 제제 |
KR20120051199A (ko) * | 2010-11-12 | 2012-05-22 | 애경산업(주) | 탈모방지 및 양모를 위한 모발 또는 두피 화장료 조성물 |
KR20140107010A (ko) * | 2013-02-27 | 2014-09-04 | 케일럽 멀티랩 (주) | 발모 촉진용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1562585E (pt) * | 2002-10-30 | 2011-02-23 | Asat Ag Applied Science & Tech | Unidades de dosagem diária de melatonina |
DE102007039745A1 (de) * | 2007-08-22 | 2009-02-26 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel mit Pflegestoff(en) und Melatonin/Agomelatin |
DE102007039741A1 (de) * | 2007-08-22 | 2009-02-26 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel mit Tensid(en) und Melatonin/Agomelatin |
DE102007039743A1 (de) * | 2007-08-22 | 2009-02-26 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel mit Alkohol(en) und Melatonin/Agomelatin |
-
2016
- 2016-01-22 WO PCT/KR2016/000742 patent/WO2016122172A1/fr active Application Filing
- 2016-01-22 KR KR1020160008203A patent/KR101622387B1/ko active IP Right Grant
- 2016-01-22 CN CN201680007880.2A patent/CN107205908B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61212512A (ja) * | 1985-03-19 | 1986-09-20 | Shiseido Co Ltd | 養毛料 |
JP2969179B2 (ja) * | 1994-12-08 | 1999-11-02 | クレット−ロッホ、ローレ、マリア | 毛髪の成長,及び選択的には皮膚並びに爪の成長を促進し,抜け毛を防止又は抑制するための合成製剤 |
KR20050083836A (ko) * | 2002-10-30 | 2005-08-26 | 아에스아테 아게 어플라이드 사이언스 앤드 테크놀로지 | 멜라토닌, 징코 빌로바, 및 비오틴을 포함하는 제제 |
KR20120051199A (ko) * | 2010-11-12 | 2012-05-22 | 애경산업(주) | 탈모방지 및 양모를 위한 모발 또는 두피 화장료 조성물 |
KR20140107010A (ko) * | 2013-02-27 | 2014-09-04 | 케일럽 멀티랩 (주) | 발모 촉진용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CN107205908B (zh) | 2020-03-10 |
KR101622387B1 (ko) | 2016-05-20 |
CN107205908A (zh) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010016683A9 (fr) | Composition pour la prévention et le traitement de l'alopécie ou pour la pousse des cheveux | |
WO2021112398A1 (fr) | Composition comprenant de la vitamine c | |
WO2020013581A1 (fr) | Composition pour prévenir la chute des cheveux ou stimuler la repousse des cheveux | |
WO2019093608A1 (fr) | Composition pharmaceutique ou cosmétique pour prévenir ou traiter la chute des cheveux ou favoriser la pousse des cheveux | |
WO2022260454A1 (fr) | Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai | |
JP3800611B2 (ja) | 美白剤または色素沈着症改善剤 | |
WO2016122172A1 (fr) | Composition pour favoriser la santé capillaire ou la pousse des cheveux, présentant une stabilité améliorée et contenant de la mélatonine | |
WO2018080039A1 (fr) | Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune | |
WO2018164325A1 (fr) | Composition permettant de soigner les symptômes du syndrome climatère féminin | |
WO2020138834A1 (fr) | Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée | |
WO2018111042A2 (fr) | Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif | |
AU2007335379B2 (en) | Prophylactic or therapeutic agent for alopecia | |
WO2019031655A1 (fr) | Composition comprenant du thymol comme principe actif pour prévenir ou traiter les rides de la peau ou la dermatite atopique | |
WO2014189159A1 (fr) | Composition comportant de l'extrait de pharbitis nil (l.) choisy pour empêcher la perte des cheveux et pour favoriser la croissance des cheveux | |
WO2017116092A1 (fr) | Composition pour prévenir ou traiter la perte des cheveux ou stimuler la croissance des cheveux ou la restauration des cheveux comprenant de la diosmine en tant que substance active | |
WO2014003224A1 (fr) | Compositions de blanchiment de la peau comprenant de la madécassoside | |
WO2019045214A1 (fr) | Composition pour la prévention ou le traitement de la dermatite atopique | |
WO2021107381A1 (fr) | Composition comprenant de l'acide férulique et des analogues de celui-ci pour prévenir et traiter des maladies cutanées causées par une mutation génétique | |
WO2015005700A1 (fr) | Composition permettant de favoriser la repousse des cheveux et la croissance des cheveux | |
WO2018194261A1 (fr) | Utilisation thérapeutique de 4'-o-méthyl alpinum isoflavone | |
WO2019088648A1 (fr) | Composition contenant de la midorine et son utilisation | |
WO2013070018A1 (fr) | Composition comprenant de l'acide carnosique ou un dérivé de celui-ci | |
WO2021125733A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de la perte de cheveux | |
WO2023277616A1 (fr) | Composition fonctionnelle pour l'alopécie comprenant un extrait dérivé de centipeda minima | |
WO2015060677A1 (fr) | Composition contenant de l'eugénol comme principe actif pour prévenir ou traiter la dermatite atopique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16743650 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16743650 Country of ref document: EP Kind code of ref document: A1 |